Skip to Accessibility Tools Skip to Content Skip to Footer

Daklinza (daclatasvir)

How is Daklinza used to treat HCV?

Daklinza (daclatasvir) is a medication used in combination with sofosbuvir or sofosbuvir and ribavirin to treat chronic hepatitis C genotype 1 and 3 infection in adults.1 Daklinza is not a stand-alone treatment, and its safety and efficacy in children is unknown. Daklinza is a direct-acting antiviral medication acting as a hepatitis C virus NS5A (nonstructural protein 5A) inhibitor. There is a potential for hepatitis B reactivation in individuals taking Daklinza who have a history of HBV. Prior to taking Daklinza, your provider should test you for HBV and note any history you have with the condition. It is important to also consult the prescribing information for medications you are also taking in combination with Daklinza, including sofosbuvir or both sofosbuvir and ribavirin.2,3

What are the ingredients in Daklinza?

The active ingredient in Daklinza is daclatasvir.

How does Daklinza work?

Daklinza is a direct-acting antiviral, with its active ingredient inhibiting HCV NS5A. NS5A is a nonstructural protein made by the HCV virus that is important to the virus’ growth and replication. The exact mechanism by which NS5A works is unknown. The inhibitor works to eliminate these crucial proteins made by the virus utilized for RNA replication and virion assembly. In theory, by inhibiting these proteins the virus will be prevented from further growth and reproduction. Many direct-acting antivirals work in this manner, targeting proteins and specific steps in the HCV life cycle.

What are the possible side effects of Daklinza?

Multiple clinical trials evaluated the safety and efficacy of Daklinza. The most common side effects of Daklinza, when taken with sofosbuvir alone, are headache and tiredness. When taken with both sofosbuvir and ribavirin, the most common side effects are headache, tiredness, anemia (low red blood cell count), and nausea.

This is not an exhaustive list of all potential side effects of Daklinza. Talk to your healthcare provider or pharmacist for further information.

Things to note about Daklinza

There is a possibility of HBV reactivation while taking Daklinza if you have a history of HBV. Your provider will administer a blood test before starting Daklinza to monitor your risk of HBV reactivation. Reactivation of HBV could cause serious liver problems including liver failure or death.
When taking Daklinza with sofosbuvir and ribavirin there is a chance of developing bradycardia, or abnormally slow heart rate. This risk is especially prevalent in those taking amiodarone, a medicine used to treat heart conditions. Seek immediate help if you experience any of the following related to bradycardia:

  • Weakness
  • Near-fainting or fainting
  • Chest Pain
  • Dizziness
  • Confusion
  • Shortness of breath
  • Memory problems
  • Tiredness

Before staring Daklinza talk to your provider if you:

  • Have or have had hepatitis B infection
  • Have or have had liver problems other than those related to HCV
  • Have had a liver transplant
  • Have heart problems
  • Are taking any other medications, supplements, or vitamins
  • Are pregnant or are planning to become pregnant. It is not known if Daklinza will affect an unborn baby.
  • Are breastfeeding or planning to breastfeed. It is not known if Daklinza can pass through breast milk.

Alert your provider immediately if you or your partner become pregnant while on Daklinza.

Dosing information

Daklinza is a once-daily oral medication. Your doctor will determine the appropriate dosage for you. A typical dose of Daklinza, in addition to sofosbuvir or both sofosbuvir and ribavirin, is 60 mg with or without food. Do not start taking any medications without alerting your provider while on Daklinza. Do not stop taking Daklinza or change the dose of Daklinza without talking to your provider. If you miss a dose, call your healthcare provider or pharmacist. If you take too much Daklinza, seek help at your local emergency room immediately.

Written by: Casey Hribar | Last reviewed: June 2019
  1. Daklinza Prescribing Information. Bristol-Myers Squibb. Feb 2017. Available from:
  2. Sovaldi (sofosbuvir) Prescribing Information. Gilead Sciences. Aug 2015. Available from:
  3. Copegus (ribavirin) Prescribing Information. Aug 2011. Available from: